Public Meeting of the Presidential Commission for the Study of Bioethical Issues
Notice Of Meeting.
The Presidential Commission for the Study of Bioethical Issues will conduct its ninth meeting in May. At this meeting, the Commission will discuss topics related to the ethical issues associated with the development of medical countermeasures for children as well as access to, and privacy of, human genome sequence data.
Table of Contents Back to Top
DATES: Back to Top
The meeting will take place on Thursday, May 17, 2012, from 9 a.m. to approximately 5:30 p.m.
ADDRESSES: Back to Top
The Embassy Row Hotel, 2015 Massachusetts Ave. NW., Washington, DC 20036. Telephone: (202) 265-1600.
FOR FURTHER INFORMATION CONTACT: Back to Top
Hillary Wicai Viers, Communications Director, Presidential Commission for the Study of Bioethical Issues, 1425 New York Ave. NW., Suite C-100, Washington, DC 20005. Telephone: (202) 233-3960. Email: Hillary.Viers@bioethics.gov. Additional information may be obtained at www.bioethics.gov.
SUPPLEMENTARY INFORMATION: Back to Top
Pursuant to the Federal Advisory Committee Act of 1972, 92, 5 U.S.C. app. 2, notice is hereby given of the ninth meeting of the Presidential Commission for the Study of Bioethical Issues (the Commission). The meeting will be open to the public with attendance limited to available space. The meeting will also be webcast at http://www.bioethics.gov.
Under authority of Executive Order 13521, dated November 24, 2009, the President established the Commission. The Commission is an advisory panel of the nation's leaders in medicine, science, ethics, religion, law, and engineering. The Commission advises the President on bioethical issues arising from advances in biomedicine and related areas of science and technology. The Commission seeks to identify and promote policies and practices that ensure scientific research, health care delivery, and technological innovation are conducted in a socially and ethically responsible manner.
The main agenda items for the Commission's ninth meeting are, first, to discuss the ethical issues associated with the development of medical countermeasures for children, and second, to discuss issues of privacy of, and access to, human genome sequence data.
The draft meeting agenda and other information about the Commission, including information about access to the webcast, will be available at http://www.bioethics.gov.
The Commission welcomes input from anyone wishing to provide public comment on any issue before it. Respectful debate of opposing views and active participation by citizens in public exchange of ideas enhances overall public understanding of the issues at hand and conclusions reached by the Commission. The Commission is particularly interested in receiving comments and questions during the meeting that are responsive to specific sessions. Written comments will be accepted at the registration desk and comment forms will be provided to members of the public in order to write down questions and comments for the Commission as they arise. To accommodate as many individuals as possible, the time for each question or comment may be limited. If the number of individuals wishing to pose a question or make a comment is greater than can reasonably be accommodated during the scheduled meeting, the Commission may make a random selection.
Anyone planning to attend the meeting who needs special assistance, such as sign language interpretation or other reasonable accommodations, should notify Esther Yoo by telephone at (202) 233-3960, or email at Esther.Yoo@bioethics.gov in advance of the meeting. The Commission will make every effort to accommodate persons who need special assistance.
Written comments will also be accepted in advance of the meeting and are especially welcome. Please address written comments by email to firstname.lastname@example.org, or by mail to the following address: Public Commentary, Presidential Commission for the Study of Bioethical Issues, 1425 New York Ave. NW., Suite C-100, Washington, DC 20005. Comments will be publicly available, including any personally identifiable or confidential business information that they contain. Trade secrets should not be submitted.
Dated: April 23, 2012.
Lisa M. Lee,
Executive Director, Presidential Commission for the Study of Bioethical Issues.
[FR Doc. 2012-10513 Filed 5-1-12; 8:45 am]
BILLING CODE 4154-06-P